BRIEF-FDA grants orphan-drug designation to ProMetic's plasminogen drug

March 14 (Reuters) - ProMetic Life Sciences Inc :

* US FDA grants orphan-drug designation to ProMetic's plasma-derived

plasminogen drug

* Says orphan drug designation is for the treatment of hypoplasminogenemia, or

type I plasminogen deficiency

* Source text * Further company coverage ((Bangalore Newsroom; +1 646 223 8780))

View the original article here